News & Updates

Show Multimedia Only
Early switching to long-acting CAB + RPV expands treatment options for people with HIV-1

Early switching to long-acting CAB + RPV expands treatment options for people with HIV-1

11 Nov 2026 byDr. Thomas Chik, Specialist in Infectious Disease, Hong Kong

Oral antiretroviral therapy (ART) has transformed HIV care, enabling durable virologic suppression and substantially reducing HIV-related morbidity and mortality. However, maintaining virologic suppression requires consistent adherence. In an interview with MIMS Doctor, Dr Thomas Chik, Specialist in Infectious Disease in Hong Kong, discussed how people living with HIV (PLHIV) who achieve HIV RNA <50 copies/mL with oral therapy can be switched early to long-acting cabotegravir plus rilpivirine (CAB + RPV LA), which improves adherence. This is suitable for a range of PLHIV, including those who are new to ART.

11 Nov 2026